Media stories about Enanta Pharmaceuticals (NASDAQ:ENTA) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.7191962163847 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Enanta Pharmaceuticals Inc (ENTA) Expected to Post Quarterly Sales of $30.01 Million (americanbankingnews.com)
- Analysts Expect Enanta Pharmaceuticals Inc (ENTA) to Post $0.10 EPS (americanbankingnews.com)
- Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing (finance.yahoo.com)
- Annual HC Wainwright NASH Investor Conference – Business Wire (press release) (businesswire.com)
ENTA has been the topic of a number of research reports. TheStreet raised shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, December 13th. Royal Bank of Canada lifted their price objective on shares of Enanta Pharmaceuticals from $54.00 to $58.00 and gave the company an “outperform” rating in a research report on Tuesday, November 21st. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. ValuEngine upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Finally, BidaskClub cut shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 10th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Enanta Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $57.40.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.